Evidence map›Paper›PMID 30586702›Full record

ArticleCirculation2019

Antiangiogenic VEGF

Vijay Chaitanya Ganta, Min Choi, Charles R Farber, Brian H Annex

Open access · bronzeAbstract read
In one paragraph

Article in Circulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 3 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Characterizing the effect of bariatric surgery on circulating S100A9.International journal of obesity (2005) · 2025
    Article
  18. Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vijay Chaitanya GantaRobert M. Berne Cardiovascular Research Center (V.C.G., M.C., B.H.A.), University of Virginia, Charlottesville.
Min ChoiRobert M. Berne Cardiovascular Research Center (V.C.G., M.C., B.H.A.), University of Virginia, Charlottesville.
Charles R FarberDepartment of Public Health Sciences (C.R.F.), University of Virginia, Charlottesville.
Brian H AnnexRobert M. Berne Cardiovascular Research Center (V.C.G., M.C., B.H.A.), University of Virginia, Charlottesville.
University of Virginia · US

Funding

Systems Biology of Angiogenesis in Peripheral Arterial DiseaseR01HL101200 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2010 to 2022
$10.7M
A Bioengineering Approach to Gene Therapy for Peripheral Arterial DiseaseR01HL116455 · NHLBI · UNIVERSITY OF VIRGINIA · PI ANNEX, BRIAN H, FRENCH, BRENT A · 2014 to 2017
$2.7M
The Anti-angiogenic VEGF165b and VEGFR1 Signaling in Peripheral Artery DiseaseR01HL141325 · NHLBI · UNIVERSITY OF VIRGINIA · PI ANNEX, BRIAN H · 2019 to 2022
$2.7M
New Roles for VEGFR1 in AngiogenesisR01GM129074 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI MAC GABHANN, FEILIM C · 2018 to 2021
$2.6M
MicroRNA 93 in Peripheral Arterial DiseaseR01HL121635 · NHLBI · UNIVERSITY OF VIRGINIA · PI ANNEX, BRIAN H · 2014 to 2017
$1.6M
NHLBI NIH HHS R01 HL101200NHLBI NIH HHS R01 HL116455NHLBI NIH HHS R01 HL121635NHLBI NIH HHS R01 HL141325NIGMS NIH HHS R01 GM129074
6 · The paper itself

Abstract

backgroundAtherosclerotic occlusions decrease blood flow to the lower limbs, causing ischemia and tissue loss in patients with peripheral artery disease (PAD). No effective medical therapies are currently available to induce angiogenesis and promote perfusion recovery in patients with severe PAD. Clinical trials aimed at inducing vascular endothelial growth factor (VEGF)-A levels, a potent proangiogenic growth factor to induce angiogenesis, and perfusion recovery were not successful. Alternate splicing in the exon-8 of VEGF-A results in the formation of VEGFxxxa (VEGF

methodsFemoral artery ligation and resection were used as an in vivo preclinical PAD model, and hypoxia serum starvation was used as an in vitro model for PAD. Experiments including laser-Doppler perfusion imaging, adoptive cell transfer to ischemic muscle, immunoblot analysis, ELISAs, immunostainings, flow cytometry, quantitative polymerase chain reaction analysis, and RNA sequencing were performed to determine a role of VEGF

resultsFirst, we found increased VEGF

conclusionsIn our current study, we demonstrate that increased VEGF

Indexed as

Neovascularization, PhysiologicAnimalsCalcium SignalingCalgranulin ACalgranulin BCells, CulturedDisease Models, AnimalEndothelial CellsHumansIschemiaMacrophagesMice, 129 StrainMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutMuscle, SkeletalCalgranulin ACalgranulin BFlt1 protein, mouseS100A8 protein, humanS100a8 protein, mouseS100A9 protein, humanS100A9 protein, mouseVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseVascular Endothelial Growth Factor Receptor-1VEGFA protein, humanalternative splicingangiogenesis inducing agentsautocrine communicationcell communicationintercellular signaling peptides and proteinsparacrine communicationtherapeutics

Identifiers

PMID30586702
PMCPMC6322929
OpenAlexW2903371348

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.